US 12,070,464 B2
Methods of treating myeloproliferative disorders
Adrian Senderowicz, Somerville, MA (US); and Michael Cooper, Cambridge, MA (US)
Assigned to Constellation Pharmaceuticals, Inc., Boston, MA (US)
Filed by Constellation Pharmaceuticals, Inc., Cambridge, MA (US)
Filed on Apr. 1, 2022, as Appl. No. 17/711,872.
Application 17/711,872 is a continuation of application No. 17/411,221, filed on Aug. 25, 2021, abandoned.
Application 17/411,221 is a continuation of application No. 17/145,748, filed on Jan. 11, 2021, abandoned.
Application 17/145,748 is a continuation of application No. 17/065,316, filed on Oct. 7, 2020, granted, now 10,918,646, issued on Feb. 16, 2021.
Application 17/065,316 is a continuation of application No. PCT/US2019/063515, filed on Nov. 27, 2019.
Prior Publication US 2023/0053604 A1, Feb. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/55 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/55 (2013.01) [A61P 35/00 (2018.01)] 17 Claims
 
1. A method of treating myelofibrosis in a subject comprising administering to the subject from 100 mg/day to 300 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide.